Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2021 - 2025)

Kiniksa Pharmaceuticals International's Other Non-Current Assets history spans 5 years, with the latest figure at $11.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 9.62% year-over-year to $11.3 million; the TTM value through Dec 2025 reached $11.3 million, up 9.62%, while the annual FY2025 figure was $11.3 million, 9.62% up from the prior year.
  • Other Non-Current Assets reached $11.3 million in Q4 2025 per KNSA's latest filing, up from $8.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $11.3 million in Q4 2025 to a low of $827000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $6.2 million, with a median of $5.9 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 85.8% in 2023, then skyrocketed 1147.28% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $8.7 million in 2021, then plummeted by 33.21% to $5.8 million in 2022, then tumbled by 85.8% to $827000.0 in 2023, then surged by 1147.28% to $10.3 million in 2024, then rose by 9.62% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Non-Current Assets are $11.3 million (Q4 2025), $8.3 million (Q3 2025), and $8.2 million (Q2 2025).